Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells. It is not
yet known whether cisplatin, etoposide, and paclitaxel are more effective than cisplatin and
etoposide alone in treating patients with extensive-stage small cell lung cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin plus etoposide
with or without paclitaxel in treating patients with extensive-stage small cell lung cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborators:
Eastern Cooperative Oncology Group National Cancer Institute (NCI) North Central Cancer Treatment Group Southwest Oncology Group